Goldman Sachs Group Inc Ventyx Biosciences, Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 593,248 shares of VTYX stock, worth $1.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
593,248
Previous 593,248 -0.0%
Holding current value
$1.33 Million
Previous $682,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
SELL
$1.15 - $2.52 $1.06 Million - $2.31 Million
-917,509 Reduced 60.73%
593,248 $682,000
Q4 2024

Feb 11, 2025
SELL
$1.72 - $3.12 $729,749 - $1.32 Million
-424,273 Reduced 21.93%
1,510,757 $3.31 Million
Q3 2024

Nov 14, 2024
BUY
$1.85 - $3.2 $880,413 - $1.52 Million
475,899 Added 32.62%
1,935,030 $4.22 Million
Q2 2024

Aug 13, 2024
SELL
$2.31 - $5.59 $519,650 - $1.26 Million
-224,957 Reduced 13.36%
1,459,131 $3.37 Million
Q1 2024

May 15, 2024
BUY
$1.9 - $10.13 $610,468 - $3.25 Million
321,299 Added 23.58%
1,684,088 $9.26 Million
Q4 2023

Feb 13, 2024
SELL
$2.08 - $31.18 $525,734 - $7.88 Million
-252,757 Reduced 15.65%
1,362,789 $3.37 Million
Q3 2023

May 14, 2024
BUY
$29.8 - $40.3 $7.53 Million - $10.2 Million
252,757 Added 18.55%
1,615,546 $56.1 Million
Q3 2023

Nov 14, 2023
BUY
$29.8 - $40.3 $1.42 Million - $1.92 Million
47,726 Added 3.04%
1,615,546 $56.1 Million
Q2 2023

May 14, 2024
BUY
$28.53 - $39.55 $6.2 Million - $8.59 Million
217,280 Added 16.09%
1,567,820 $51.4 Million
Q2 2023

Aug 14, 2023
BUY
$28.53 - $39.55 $6.2 Million - $8.59 Million
217,280 Added 16.09%
1,567,820 $51.4 Million
Q1 2023

May 14, 2024
BUY
$29.51 - $46.65 $38.5 Million - $60.8 Million
1,304,211 Added 2815.11%
1,350,540 $45.2 Million
Q1 2023

May 11, 2023
BUY
$29.51 - $46.65 $38.5 Million - $60.8 Million
1,304,211 Added 2815.11%
1,350,540 $45.2 Million
Q4 2022

May 14, 2024
BUY
$24.16 - $36.38 $533,597 - $803,488
22,086 Added 91.1%
46,329 $1.52 Million
Q4 2022

Feb 13, 2023
BUY
$24.16 - $36.38 $533,597 - $803,488
22,086 Added 91.1%
46,329 $1.52 Million
Q3 2022

May 14, 2024
BUY
$12.64 - $38.7 $67,940 - $208,012
5,375 Added 28.49%
24,243 $846,000
Q3 2022

Nov 10, 2022
BUY
$12.64 - $38.7 $67,940 - $208,012
5,375 Added 28.49%
24,243 $846,000
Q2 2022

May 14, 2024
SELL
$11.95 - $18.75 $16.1 Million - $25.2 Million
-1,343,921 Reduced 98.62%
18,868 $231,000
Q2 2022

Aug 15, 2022
BUY
$11.95 - $18.75 $225,472 - $353,775
18,868 New
18,868 $231,000

Others Institutions Holding VTYX

# of Institutions
126
Shares Held
45.4M
Call Options Held
35.2K
Put Options Held
40.6K
View Full List

About Ventyx Biosciences, Inc.

VTYX Quotes by TradingView
  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $127M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email